EZH2 and acute myeloid leukemia: We observed that EZH2 is highly expressed in AML patients, and the high expression is associated with poor outcomes (low CR rate, high refractory/relapse rate, and short OS) in the patients, but the EZH2-high expression was not observed to be associated with genomic defects.